Literature DB >> 23030472

MnO-labeled cells: positive contrast enhancement in MRI.

Mathieu Létourneau1, Mélanie Tremblay, Luc Faucher, Dario Rojas, Pascale Chevallier, Yves Gossuin, Jean Lagueux, Marc-André Fortin.   

Abstract

Manganese oxide (MnO) nanoparticles have been suggested as a promising "positive" MRI contrast agent for cellular and molecular studies. Mn-based contrast agents could enable T(1)-weighted quantitative cell tracking procedures in vivo based on signal enhancement. In this study, ultrasmall MnO particles were synthesized and coated with thiolated molecules (DMSA) and polyethylene glycol (PEG) to allow enhanced cell labeling properties and colloidal stability. This coating allowed the fabrication of individual ultrasmall nanoparticles of MnO (USPMnO) as well as of nanoaggregates of the same material (SPMnO). Particle size was measured by TEM and DLS. Physico-chemical properties were characterized by XPS and FTIR. The relaxometric properties of these aqueous suspensions were measured at various magnetic fields. The suspensions provided strong positive contrast enhancement in T(1)-weighted imaging due to high longitudinal relaxivities (r(1)) and low r(2)/r(1) ratios (USPMnO: r(1) = 3.4 ± 0.1 mM(-1)s(-1), r(2)/r(1) = 3.2; SPMnO: r(1) = 17.0 ± 0.5 mM(-1)s(-1), r(2)/r(1) = 4.0, at 1.41T). HT-1080 cancer cells incubated with the contrast agents were clearly visualized in MRI for Mn contents >1.1 pg Mn/cell. The viability of cells was not affected, contrarily to cells labeled with an equivalent concentration of Mn(2+) ions. A higher signal per cell was found for SPMnO-labeled compared with USPMnO-labeled cells, due to the higher relaxometric properties of the agglomerates. As a result, the "positive" signal enhancement effect is not significantly affected upon agglomeration of MnO particles in endosomes. This is a major requirement in the development of reliable cell tracking procedures using T(1)-weighted imaging sequences. This study confirms the potential of SPMnO and USPMnO to establish more quantitative cell tracking procedures with MRI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23030472     DOI: 10.1021/jp3032918

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  7 in total

1.  Highly water-dispersible calcium lignosulfonate-capped MnO nanoparticles as a T 1 MRI contrast agent with exceptional colloidal stability, low toxicity and remarkable relaxivity.

Authors:  Mahdi Arian; Ali Zamanian; Salman Taheri
Journal:  RSC Adv       Date:  2019-12-06       Impact factor: 4.036

2.  D-Alpha-Tocopheryl Poly(ethylene Glycol 1000) Succinate-Coated Manganese-Zinc Ferrite Nanomaterials for a Dual-Mode Magnetic Resonance Imaging Contrast Agent and Hyperthermia Treatments.

Authors:  Lin Wang; Syu-Ming Lai; Cun-Zhao Li; Hsiu-Ping Yu; Parthiban Venkatesan; Ping-Shan Lai
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

Review 3.  Engineering of inorganic nanoparticles as magnetic resonance imaging contrast agents.

Authors:  Dalong Ni; Wenbo Bu; Emily B Ehlerding; Weibo Cai; Jianlin Shi
Journal:  Chem Soc Rev       Date:  2017-11-27       Impact factor: 54.564

Review 4.  Nanoparticles and clinically applicable cell tracking.

Authors:  Monique R Bernsen; Jamal Guenoun; Sandra T van Tiel; Gabriel P Krestin
Journal:  Br J Radiol       Date:  2015-08-07       Impact factor: 3.629

Review 5.  The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.

Authors:  Xiaodong Li; Yanhong Sun; Lina Ma; Guifeng Liu; Zhenxin Wang
Journal:  Molecules       Date:  2020-11-01       Impact factor: 4.411

6.  Manganese dioxide nanosheets-based redox/pH-responsive drug delivery system for cancer theranostic application.

Authors:  Yongwei Hao; Lei Wang; Bingxiang Zhang; Dong Li; Dehui Meng; Jinjin Shi; Hongling Zhang; Zhenzhong Zhang; Yun Zhang
Journal:  Int J Nanomedicine       Date:  2016-04-29

Review 7.  Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives.

Authors:  Ethel J Ngen; Dmitri Artemov
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.